Skip to main
SLGL

Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies (SLGL) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sol-Gel Technologies is a dermatology company with a promising pipeline of product candidates, including SGT-610, a topical drug targeting the hedgehog signaling pathway for the treatment of Gorlin syndrome. The release of top-line data from the pivotal Phase 3 trial of SGT-610 is expected to occur in late 2026, with potential FDA approval and launch in 2027 and 2028, respectively. With a potential peak revenue exceeding $300M annually, SGT-610 has the potential to be a significant value driver for the company.

Bears say

Sol-Gel Technologies is facing significant risks to achieving its price objectives, with potential setbacks in key clinical trials such as the failure of SGT-610 pivotal trial in Gorlin syndrome and the inability to secure U.S. regulatory approval for SGT-610. The recent negative results from the topical erlotinib clinical study for SGT-210 in Darier disease and its discontinuation for further development in this indication also add to the risks and may impact the company's valuation in the future. However, the company's plans to continue exploring potential future applications for SGT-210 through small, targeted proof-of-concept studies may provide some potential upside.

Sol-Gel Technologies (SLGL) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sol-Gel Technologies (SLGL) Forecast

Analysts have given Sol-Gel Technologies (SLGL) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Sol-Gel Technologies (SLGL) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sol-Gel Technologies (SLGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.